Nearly all postmenopausal women with early-stage HR+ breast cancer are treated with aromatase inhibitors. But these drugs can significantly compromise bone health and up the risk of fractures.

The risk of broken bones increases with age and is a major cause of disability and death in older people. But some treatments may prevent bone fractures.

Women with osteoporosis (brittle bones) have two effective treatment choices: Prolia (denosumab) and Reclast (zoledronic acid). So which is more effective? A recent study did a side-by-side comparison.

When one medicine doesn't help postmenopausal women with osteoporosis, doctors might recommend another. But if the second doesn't strengthen bones, what happens then? Taking them together might do the trick.